Literature DB >> 25083224

Statins and their interactions with other lipid-modifying medications: safety issues in the elderly.

Clement K M Ho, Simon W Walker.   

Abstract

Inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, commonly known as statins, are widely used in both primary and secondary prevention of occlusive cardiovascular disease. Statins are effective not only in improving total and low-density lipoprotein cholesterol concentrations in blood but also in decreasing morbidity and mortality associated with cardiovascular diseases resulting from underlying atheroma. There is, however, evidence that statins are underutilized in elderly patients, possibly due to concerns about safety/tolerability issues or potential drug interactions, including interactions with other lipid-modifying medications, or both. In this review, we summarize the major adverse events associated with statin use, with particular reference to the elderly patient, including factors which might increase the risk of adverse effects. Potential drug interactions between statins and other lipid-modifying medications including fibrates, ezetimibe, nicotinic acid, bile acid sequestrants and omega-3-acid ethyl esters (fish oils) are specifically discussed. Clinical management strategies to avoid these drug interactions are outlined.

Entities:  

Keywords:  adverse effects; bile acid sequestrants; drug–drug interactions; elderly; ezetimibe; fibrates; fish oil; nicotinic acid; statins

Year:  2012        PMID: 25083224      PMCID: PMC4110829          DOI: 10.1177/2042098611428486

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  72 in total

Review 1.  Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Authors:  Stefano Bellosta; Rodolfo Paoletti; Alberto Corsini
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

Review 2.  Aging biology and geriatric clinical pharmacology.

Authors:  Allan J McLean; David G Le Couteur
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

3.  Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

Authors:  James E Patrick; Teddy Kosoglou; Kathe L Stauber; Kevin B Alton; Stephen E Maxwell; Yali Zhu; Paul Statkevich; Robert Iannucci; Swapan Chowdhury; Melton Affrime; Mitchell N Cayen
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

4.  An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.

Authors:  P N Durrington; D Bhatnagar; M I Mackness; J Morgan; K Julier; M A Khan; M France
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

5.  Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

Authors:  James McKenney; Harold Bays; Michael Koren; Christie M Ballantyne; John F Paolini; Yale Mitchel; Abigaile Betteridge; Olga Kuznetsova; Aditi Sapre; Christine McCrary Sisk; Darbie Maccubbin
Journal:  J Clin Lipidol       Date:  2010-02-12       Impact factor: 4.766

Review 6.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

7.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

8.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

9.  Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

Authors:  Christie M Ballantyne; Michael H Davidson; James McKenney; Laurence H Keller; Daiva R Bajorunas; Richard H Karas
Journal:  Am J Cardiol       Date:  2008-05-15       Impact factor: 2.778

10.  Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.

Authors:  Carl Kyrklund; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

View more
  4 in total

Review 1.  Prevalence of statin-drug interactions in older people: a systematic review.

Authors:  Michele Thai; Emily Reeve; Sarah N Hilmer; Katie Qi; Sallie-Anne Pearson; Danijela Gnjidic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

Review 2.  Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV.

Authors:  Stephani C Wang; Gurleen Kaur; Joshua Schulman-Marcus; Scott Purga; Sulagna Mookherjee; Cyndi Miller; Mandeep S Sidhu; Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-26       Impact factor: 3.727

3.  Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.

Authors:  Donatella Zodda; Rosario Giammona; Silvia Schifilliti
Journal:  Pharmacy (Basel)       Date:  2018-01-21

4.  Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data.

Authors:  So Mi Jemma Cho; Hokyou Lee; Hyeok-Hee Lee; Jongmin Baek; Ji Eun Heo; Hyung Joon Joo; Soon Jun Hong; Hyeon Chang Kim
Journal:  J Lipid Atheroscler       Date:  2021-04-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.